Search research articles
Contact Us
Filters
Showing results (1-10 of 9) with videos related to
Page
of 1
Sort By:
Nature Genetics
|
October 28, 2004
Will tomorrow's medicines work for everyone?
Sarah K Tate, David B Goldstein
Expert Opinion on Pharmacotherapy
|
July 31, 2007
Multidrug resistance in epilepsy: a pharmacogenomic update
Sarah K Tate, Sanjay M Sisodiya
Nature Reviews. Genetics
|
November 25, 2003
Pharmacogenetics goes genomic
David B Goldstein, Sarah K Tate, Sanjay M Sisodiya
American Journal of Human Genetics
|
April 17, 2007
Nova2 interacts with a cis-acting polymorphism to influence the proportions of drug-responsive splice variants of SCN1A
Erin L Heinzen, Woohyun Yoon, Sarah K Tate, et al.
Pharmacogenetics and Genomics
|
September 27, 2006
A common polymorphism in the SCN1A gene associates with phenytoin serum levels at maintenance dose
Sarah K Tate, Rinki Singh, Chin-Chuan Hung, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
April 5, 2005
Genetic predictors of the maximum doses patients receive during clinical use of the anti-epileptic drugs carbamazepine and phenytoin
Sarah K Tate, Chantal Depondt, Sanjay M Sisodiya, et al.
The Lancet. Neurology
|
October 5, 2007
Multicentre search for genetic susceptibility loci in sporadic epilepsy syndrome and seizure types: a case-control study
Gianpiero L Cavalleri, Michael E Weale, Kevin V Shianna, et al.
Brain : a Journal of Neurology
|
June 5, 2010
Common genetic variation and susceptibility to partial epilepsies: a genome-wide association study
Dalia Kasperaviciūte, Claudia B Catarino, Erin L Heinzen, et al.
American Journal of Human Genetics
|
April 20, 2010
Rare deletions at 16p13.11 predispose to a diverse spectrum of sporadic epilepsy syndromes
Erin L Heinzen, Rodney A Radtke, Thomas J Urban, et al.
Page
of 1
Search research articles
Search
Showing results (1-10 of 9) with videos related to
Sort By:
Page
of 1
Nature Genetics
|
October 28, 2004
Will tomorrow's medicines work for everyone?
Sarah K Tate, David B Goldstein
Expert Opinion on Pharmacotherapy
|
July 31, 2007
Multidrug resistance in epilepsy: a pharmacogenomic update
Sarah K Tate, Sanjay M Sisodiya
Nature Reviews. Genetics
|
November 25, 2003
Pharmacogenetics goes genomic
David B Goldstein, Sarah K Tate, Sanjay M Sisodiya
American Journal of Human Genetics
|
April 17, 2007
Nova2 interacts with a cis-acting polymorphism to influence the proportions of drug-responsive splice variants of SCN1A
Erin L Heinzen, Woohyun Yoon, Sarah K Tate, et al.
Pharmacogenetics and Genomics
|
September 27, 2006
A common polymorphism in the SCN1A gene associates with phenytoin serum levels at maintenance dose
Sarah K Tate, Rinki Singh, Chin-Chuan Hung, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
April 5, 2005
Genetic predictors of the maximum doses patients receive during clinical use of the anti-epileptic drugs carbamazepine and phenytoin
Sarah K Tate, Chantal Depondt, Sanjay M Sisodiya, et al.
The Lancet. Neurology
|
October 5, 2007
Multicentre search for genetic susceptibility loci in sporadic epilepsy syndrome and seizure types: a case-control study
Gianpiero L Cavalleri, Michael E Weale, Kevin V Shianna, et al.
Brain : a Journal of Neurology
|
June 5, 2010
Common genetic variation and susceptibility to partial epilepsies: a genome-wide association study
Dalia Kasperaviciūte, Claudia B Catarino, Erin L Heinzen, et al.
American Journal of Human Genetics
|
April 20, 2010
Rare deletions at 16p13.11 predispose to a diverse spectrum of sporadic epilepsy syndromes
Erin L Heinzen, Rodney A Radtke, Thomas J Urban, et al.
Page
of 1